MiR-26a-5p Regulates Proliferation, Apoptosis, Migration and Invasion Via Inhibiting Hydroxysteroid Dehydrogenase Like-2 in Cervical Cancer Cell

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2022 Aug 10

PMID 35948893

Authors

Ming Li

Yubo Xiao

Minqi Liu

Qian Ning

Ziye Xiang

Xiang Zheng

Shengsong Tang

Zhongcheng Mo

Affiliations

Soon will be listed here.

Abstract

Background: Evidences have indicated that miR-26a-5p regulates the malignant properties of various tumor cells. However, the influences of miR-26a-5p on proliferation, apoptosis and invasion are still vague in the cervical cancer (CC) cells.

Methods: The miRNA microarray and real-time quantitative PCR (RT-qPCR) analysis were utilized to detect the expression of miR-26a-5p in the patients with CC. Kaplan-Meier plotter was performed to evaluate the overall survival (OS) of the patients with CC. The CCK-8, flow cytometry, transwell and wound healing analyses were respectively used to analyze proliferation, migration and invasion in the CC cells. RT-qPCR, western blot and IHC analysis were executed to measure the expression of hydroxysteroid dehydrogenase like-2 (HSDL2) in the patients with CC. Bioinformatics and luciferase reporter assay were carried out to verify the relationship of miR-26a-5p and HSDL2.

Results: The expression of miR-26a-5p was downregulated and low expression of miR-26a-5p indicated a poor OS in patients with CC. Overexpression of miR-26a-5p significantly inhibited proliferation, migration and invasion, accelerated apoptosis in the Hela and C33A cells. The expression of HSDL2 was upregulated, and negatively correlated with miR-26a-5p in the patients with CC. HSDL2 was directly targeted by miR-26a-5p and rescue experiments displayed that HSDL2 partially abolished proliferation, apoptosis, migration, and invasion induced by miR-26a-5p in CC cells.

Conclusions: MiR-26a-5p alleviated progression of CC by suppressing proliferation, migration and invasion, promoting apoptosis through downregulating HSDL2.

Citing Articles

Computational Elucidation of Hub Genes and Pathways Correlated with the Development of 5-Fluorouracil Resistance in HCT 116 Colorectal Carcinoma Cell Line.

Tan C, Lim S, Sim K Biochem Genet. 2025; .

PMID: 39883358 DOI: 10.1007/s10528-025-11041-2.

Emerging roles of non-coding RNAs in modulating the PI3K/Akt pathway in cancer.

Hashemi M, Khosroshahi E, Asadi S, Tanha M, Ghatei Mohseni F, Abdolmohammad Sagha R Noncoding RNA Res. 2024; 10:1-15.

PMID: 39296640 PMC: 11406677. DOI: 10.1016/j.ncrna.2024.08.002.

Evaluating the Serum Level of ACTH and Investigating the Expression of miR-26a, miR-34a, miR-155-5p, and miR-146a in the Peripheral Blood Cells of Multiple Sclerosis Patients.

Al-Dahimavi S, Safaralizadeh R, Khalaj-Kondori M Biochem Genet. 2024; .

PMID: 39223335 DOI: 10.1007/s10528-024-10909-z.

Inhibitory effect of Curcumin on a cervical cancer cell line via the RAS/RAF signaling pathway.

Ozdemir I, Zaman F, Dogan Bas D, Sari U, Ozturk S, Tuncer M Histol Histopathol. 2024; 40(3):327-334.

PMID: 39092501 DOI: 10.14670/HH-18-797.

MicroRNA-19a-3p inhibits endothelial dysfunction in atherosclerosis by targeting JCAD.

Luo J, Wang L, Cui C, Chen H, Zeng W, Li X BMC Cardiovasc Disord. 2024; 24(1):394.

PMID: 39080547 PMC: 11287888. DOI: 10.1186/s12872-024-04063-y.

References

Han A, Xu R, Liu Y, Yin X, Lin Z, Yang W . HSDL2 Acts as a Promoter in Pancreatic Cancer by Regulating Cell Proliferation and Lipid Metabolism. Onco Targets Ther. 2021; 14:435-444. PMC: 7814248. DOI: 10.2147/OTT.S287722. View

Liu Y, Cai Y, Chang Y . Dual inhibition of RNAi therapeutic miR-26a-5p targeting cMet and immunotherapy against EGFR in endometrial cancer treatment. Ann Transl Med. 2021; 9(1):5. PMC: 7859788. DOI: 10.21037/atm-20-3166. View

Wang R, Long X, Zhou N, Chen D, Zhang M, Wen Z . Lnc-GAN1 expression is associated with good survival and suppresses tumor progression by sponging mir-26a-5p to activate PTEN signaling in non-small cell lung cancer. J Exp Clin Cancer Res. 2021; 40(1):9. PMC: 7786923. DOI: 10.1186/s13046-020-01819-0. View

Sun Q, Zhang Y, Su J, Li T, Jiang Y . Role of Hydroxysteroid Dehydrogenase-Like 2 (HSDL2) in Human Ovarian Cancer. Med Sci Monit. 2018; 24:3997-4008. PMC: 6029517. DOI: 10.12659/MSM.909418. View

Zhang D, Liu Z, Lu Z, Sun W, Ma X, Zhang P . Lentivirus-mediated overexpression of HSDL2 suppresses cell proliferation and induces apoptosis in cholangiocarcinoma. Onco Targets Ther. 2018; 11:7133-7142. PMC: 6200078. DOI: 10.2147/OTT.S176410. View

Wang Z, Liu T, Xue W, Fang Y, Chen X, Xu L . ARNTL2 promotes pancreatic ductal adenocarcinoma progression through TGF/BETA pathway and is regulated by miR-26a-5p. Cell Death Dis. 2020; 11(8):692. PMC: 7443143. DOI: 10.1038/s41419-020-02839-6. View

Tsikouras P, Zervoudis S, Manav B, Tomara E, Iatrakis G, Romanidis C . Cervical cancer: screening, diagnosis and staging. J BUON. 2016; 21(2):320-5. View

Yang Y, Han A, Wang X, Yin X, Cui M, Lin Z . Lipid metabolism regulator human hydroxysteroid dehydrogenase-like 2 (HSDL2) modulates cervical cancer cell proliferation and metastasis. J Cell Mol Med. 2021; 25(10):4846-4859. PMC: 8107089. DOI: 10.1111/jcmm.16461. View

Hsiao Y, Lin C, Wang P, Hsin M, Yang S . The Potential of Chinese Herbal Medicines in the Treatment of Cervical Cancer. Integr Cancer Ther. 2019; 18:1534735419861693. PMC: 6611015. DOI: 10.1177/1534735419861693. View

10.

Shi Y, Mao Z, Huang Y, Sun Y, Cao Q, Yin X . Knockdown of HSDL2 inhibits lung adenocarcinoma progression via down-regulating AKT2 expression. Biosci Rep. 2020; 40(4). PMC: 7138907. DOI: 10.1042/BSR20200348. View

11.

Zeng J, Ma X, Wang J, Liu R, Shao Y, Hou Y . Down-regulated expression suppresses cell proliferation and promotes apoptosis in papillary thyroid carcinoma. Biosci Rep. 2019; 39(6). PMC: 6549096. DOI: 10.1042/BSR20190425. View

12.

Lin Y, Jian Z, Jin H, Wei X, Zou X, Guan R . Long non-coding RNA DLGAP1-AS1 facilitates tumorigenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via the feedback loop of miR-26a/b-5p/IL-6/JAK2/STAT3 and Wnt/β-catenin pathway. Cell Death Dis. 2020; 11(1):34. PMC: 6965175. DOI: 10.1038/s41419-019-2188-7. View

13.

Tan Y, Wang H, Zhang C . MicroRNA-381 targets G protein-Coupled receptor 34 (GPR34) to regulate the growth, migration and invasion of human cervical cancer cells. Environ Toxicol Pharmacol. 2020; 81:103514. DOI: 10.1016/j.etap.2020.103514. View

14.

Eskander R, Tewari K . Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer. Clin Ther. 2015; 37(1):20-38. DOI: 10.1016/j.clinthera.2014.11.010. View

15.

Wang X, He Y, Mackowiak B, Gao B . MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut. 2020; 70(4):784-795. DOI: 10.1136/gutjnl-2020-322526. View

16.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

17.

Kong Y, Zhang Y, Mao F, Zhang Z, Li Z, Wang R . Inhibition of EZH2 Enhances the Antitumor Efficacy of Metformin in Prostate Cancer. Mol Cancer Ther. 2020; 19(12):2490-2501. PMC: 7718407. DOI: 10.1158/1535-7163.MCT-19-0874. View

18.

DAddario M, Redmond S, Scott P, Egli-Gany D, Riveros-Balta A, Restrepo A . Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis. Vaccine. 2017; 35(22):2892-2901. DOI: 10.1016/j.vaccine.2017.03.096. View

19.

Koh W, Abu-Rustum N, Bean S, Bradley K, Campos S, Cho K . Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17(1):64-84. DOI: 10.6004/jnccn.2019.0001. View

20.

Li Y, Wang P, Wu L, Yan J, Pang X, Liu S . miR-26a-5p Inhibit Gastric Cancer Cell Proliferation and Invasion Through Mediated Wnt5a. Onco Targets Ther. 2020; 13:2537-2550. PMC: 7108881. DOI: 10.2147/OTT.S241199. View